The Medicines and Healthcare products Regulatory Agency (MHRA) has today authorised this new indication for Anastrozole, a hormone treatment used for breast cancer in post-menopausal women.
Anastrozole was already authorised for use in the treatment of breast cancer in post-menopausal women and has been used off-label for prevention.
Today's announcement confirms the authorisation for prevention in post-menopausal women at moderate or high risk of developing the disease.
Evidence was based on the IBIS-II study, an international, randomised double-blind, placebo-controlled trial, which showed fewer women developed breast cancer in the anastrozole group compared to the placebo group.
Breast cancer is the most common type of cancer in the UK. Most women diagnosed with breast cancer are over the age of 50, but younger women can also get breast cancer. Around 1 in 7 women will be diagnosed with breast cancer in their lifetime.
The treatment is taken as a 1mg tablet, once a day for 5 years.
Anastrozole is an aromatase inhibitor. This works by cutting down the amount of the hormone oestrogen that a patient's body makes by blocking an enzyme called 'aromatase'.
The most common side effects of the medicine are hot flushes, feeling weak, pain/stiffness in the joints, arthritis, skin rash, nausea, headache, osteoporosis, and depression.
As with any medicine, the MHRA will keep the safety and effectiveness of Anastrozole under close review. Anyone who suspects they are having a side effect from this medicine are encouraged to talk to their doctor, pharmacist or nurse and report it directly to the Yellow Card scheme, either through the website or by searching the Google Play or Apple App stores for MHRA Yellow Card.
Notes
-
Authorisation for this new indication for Anastrozole was granted on 6 November 2023 to Accord Healthcare Ltd.
